-

Tandem Diabetes Care Announces Upcoming Conference Presentations

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences:

  • BofA Securities Health Care Conference 2024 on Wednesday, May 15, 2024 at 1:00pm Eastern Time (10:00am Pacific Time), and
  • Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024 at 12:20pm Eastern Time (9:20am Pacific Time).

The Company update presentations will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care, the Tandem logo, Control-IQ, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries.

Contacts

Media Contact:
858-366-6900
media@tandemdiabetes.com

Investor Contact:
858-366-6900
IR@tandemdiabetes.com

Tandem Diabetes Care, Inc.

NASDAQ:TNDM

Release Versions

Contacts

Media Contact:
858-366-6900
media@tandemdiabetes.com

Investor Contact:
858-366-6900
IR@tandemdiabetes.com

More News From Tandem Diabetes Care, Inc.

Tandem Mobi Now FDA Cleared as World’s First and Only Tubeless AID System with up to Seven Days of Wear

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of Tandem Mobi for use as the world’s first and only tubeless automated insulin delivery system with up to 7 days of wear.1 A new Tandem Mobi tubeless cartridge and infusion set converts the current Tandem Mobi pump into a tubeless device that can help simplify diabetes management with less frequent si...

Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of Health Canada approval of a license amendment for the t:slim X2™ insulin pump with Control-IQ+™ automated insulin delivery (AID) technology. This approval adds compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor and expands the t:slim X2 system’s indications for use to people with type 1 diabetes during pregnancy and to adults with...

Tandem Diabetes Care Names Jeannette Bankes as President and Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)--Jeannette Bankes named President and CEO of Tandem Diabetes Care in planned transition as John Sheridan Retires After Over a Decade of Service...
Back to Newsroom